Literature DB >> 1915397

Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever.

G Bodey1, A Reuben, L Elting, H Kantarjian, M Keating, F Hagemeister, C Koller, W Velasquez, N Papadopoulos.   

Abstract

Cancer patients were randomized to receive an every 4 hour or every 8 hour schedule of cefoperazone plus aztreonam during 617 febrile episodes. The overall response rate for the 478 evaluable episodes was 76% and there was no difference in response rate between the two schedules. The response rate was 79% for cases of pneumonia and 63% for cases of bacteremia. Only 50% of the microbiologically documented infections caused by gram-positive organisms responded whereas 95% of gram-negative infections, including all of those caused by Pseudomonas aeruginosa, responded. Response rates were lower among patients whose neutrophil counts decreased during therapy than among those whose neutrophil counts increased (64% vs. 85%, p = 0.008). Side-effects that were possibly or probably related to antibiotic therapy were observed during 11% of the episodes. The most common side-effects were diarrhea and rashes including one case of Stevens-Johnson syndrome. Three patients developed a coagulopathy during therapy. Cefoperazone plus aztreonam proved to be an effective combination for treatment of gram-negative infections and fever of unknown origin in cancer patients and an every 8-hour schedule of administration was as effective as an every 4-hour schedule. Approximately half of the patients with gram-positive infections required additional antibiotics for successful therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915397     DOI: 10.1007/bf01967272

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia.

Authors:  M Rubin; J W Hathorn; D Marshall; J Gress; S M Steinberg; P A Pizzo
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

2.  Antibiotic combinations for infections in neutropenic patients. Evaluaton of carbenicillin plus either cephalothin or kanamycin.

Authors:  E L Middleman; A Watanabe; H Kaizer; G P Bodey
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

3.  Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients.

Authors:  V Fainstein; G P Bodey; R Bolivar; L Elting; K B McCredie; M J Keating
Journal:  Arch Intern Med       Date:  1984-09

4.  A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients.

Authors:  G P Bodey; S J Ketchel; V Rodriguez
Journal:  Am J Med       Date:  1979-10       Impact factor: 4.965

5.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Klin Wochenschr       Date:  1987-08-17

6.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.

Authors:  N Frimodt-Møller; M W Bentzon; V F Thomsen
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

Review 7.  Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital.

Authors:  G P Bodey
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

8.  Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections.

Authors:  S J Weisman; F J Scoopo; G M Johnson; A J Altman; J J Quinn
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

9.  Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.

Authors:  D J Winston; R C Barnes; W G Ho; L S Young; R E Champlin; R P Gale
Journal:  Am J Med       Date:  1984-09       Impact factor: 4.965

10.  A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients.

Authors:  V Fainstein; G P Bodey; L Elting; R Bolivar; M J Keating; K B McCredie; M Valdivieso
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

View more
  1 in total

1.  Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.

Authors:  Carmen P Escalante; Mary Ann Weiser; Ellen Manzullo; Robert Benjamin; Edgardo Rivera; Tony Lam; Vi Ho; Rosalie Valdres; Eva Lu Lee; Noemi Badrina; Sally Fernandez; Yvette DeJesus; Kenneth Rolston
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.